Celecoxib + Placebo

Phase 2Completed
0 watching 0 views this week Active
51
Hype Score

Development Stage

Pre-clinical
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Colorectal Adenoma

Conditions

Colorectal Adenoma, Colorectal Carcinoma

Trial Timeline

Dec 1, 2001 → Jun 1, 2008

About Celecoxib + Placebo

Celecoxib + Placebo is a phase 2 stage product being developed by Pfizer for Colorectal Adenoma. The current trial status is completed. This product is registered under clinical trial identifier NCT00582660. Target conditions include Colorectal Adenoma, Colorectal Carcinoma.

Hype Score Breakdown

Clinical
17
Activity
12
Company
9
Novelty
5
Community
5

Clinical Trials (11)

NCT IDPhaseStatus
NCT01186887Pre-clinicalCompleted
NCT00583453Phase 2Completed
NCT00359151ApprovedTerminated
NCT00585312Phase 3Terminated
NCT00300729Phase 3UNKNOWN
NCT00640627ApprovedCompleted
NCT00698204Phase 2Completed
NCT00639483Phase 2Completed
NCT00471341ApprovedCompleted
NCT00582660Phase 2Completed
NCT02840162Phase 2Terminated

Competing Products

20 competing products in Colorectal Adenoma

See all competitors
ProductCompanyStageHype Score
Cetuximab + Oxaliplatin + CapecitabineEli LillyPhase 2
52
IMC-1121B (ramucirumab) + Oxaliplatin + Folinic acid + 5-FU + 5-FUEli LillyPhase 2
52
ZN-c3 + Encorafenib + CetuximabZentalis PharmaceuticalsPhase 1
25
ALIMTA + OxaliplatinEli LillyPhase 2
52
eFT508 + AvelumabeFFECTOR TherapeuticsPhase 2
44
Bevacizumab + Oxaliplatin + CapecitabineChugai PharmaceuticalPhase 1/2
41
Bevacizumab + 5-fluorouracil + Leucovorin calcium + Irinotecan hydrochloride + Oxaliplatin + CapecitabineChugai PharmaceuticalPhase 2
52
FOLFIRI + FOLFOX-4 + FOLFIRI-HD + FOLFOX-7 + FOLFIRINOXChugai PharmaceuticalPhase 2/3
65
Gemcitabine and UFTE chemotherapyYuhanPhase 2
52
CPT-11 and TS-1 + CPT-11, 5-FU and l-LVDaiichi SankyoPhase 2/3
65
CPT-11 based regimensDaiichi SankyoPre-clinical
23
CS7017 + irinotecan, leucovorin, and 5-fluorouracil (5-FU) (FOLFIRI)Daiichi SankyoPhase 2
52
Tivantinib + Placebo + Cetuximab + IrinotecanDaiichi SankyoPhase 1/2
41
DS-8201a 5.4 mg/kg Q3W + DS-8201a 6.4 mg/kg Q3WDaiichi SankyoPhase 2
52
Trastuzumab deruxtecanDaiichi SankyoPhase 2
52
CS-1008 + irinotecanDaiichi SankyoPhase 2
52
CS-7017 + PlaceboDaiichi SankyoPhase 2
52
Patritumab DeruxtecanDaiichi SankyoPhase 2
52
CS-1008 + FOLFIRIDaiichi SankyoPhase 1
33
DS-8273a + nivolumabDaiichi SankyoPhase 1
33